Clinical Effect of Nituzumab Combined with Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Malignancies
Objective To analyze the value of nituzumab plus chemoradiotherapy in the treatment of locally advanced head and neck malignancies.Methods A total of 72 patients with local advanced stage of head and neck malignant tu-mors who were admitted in Tengzhou Central People's Hospital from November 2021 to November 2022 were taken as study objects.They were divided into basic group and comprehensive group with 36 cases in each group by rolling dice.The basic group received chemoradiation and chemotherapy,while the comprehensive group received nituzumab based on basic group.The short-term and long-term curative effects and adverse reaction were compared between two groups.Results The clinical remission rate(58.33%)and clinical control rate(88.89%)in comprehensive group were higher than those of the basic group(30.56%,66.67%),and the differences were statistically significant(χ2=5.625,5.143,P=0.018,0.023).The survival rate of the comprehensive group was 80.56%,which was higher than that of the basic group(58.33%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion Treatment with nituzumab during chemoradiotherapy does not induce more adverse reaction,and can maintain a high remission rate and control rate,as well as improve long-term survival rate,which is suitable for patients with locally advanced head and neck malignan-cies.
Malignant tumorHead and neckShort and long term curative effectNituzumabToxic and side effects
万方数据
维普
